By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein analysis firm Cell Biosciences today said it has entered into a definitive agreement to buy Convergent Bioscience for $12 million in a cash deal.

The deal is expected to expand Cell Biosciences' protein analysis product portfolio "and transform Cell Biosciences into the premier provider of capillary-based protein analysis technology," the Santa Clara, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.